Quantitative proteomic analysis of cultured skin fibroblast cells derived from patients with triglyceride deposit cardiomyovasculopathy by Yasuhiro Hara et al.
Hara et al. Orphanet Journal of Rare Diseases 2013, 8:197
http://www.ojrd.com/content/8/1/197RESEARCH Open AccessQuantitative proteomic analysis of cultured skin
fibroblast cells derived from patients with
triglyceride deposit cardiomyovasculopathy
Yasuhiro Hara1, Naoko Kawasaki1, Ken-ichi Hirano2, Yuuki Hashimoto1, Jun Adachi1, Shio Watanabe1
and Takeshi Tomonaga1*Abstract
Background: Triglyceride deposit cardiomyovasculopathy (TGCV) is a rare disease, characterized by the massive
accumulation of triglyceride (TG) in multiple tissues, especially skeletal muscle, heart muscle and the coronary artery.
TGCV is caused by mutation of adipose triglyceride lipase, which is an essential molecule for the hydrolysis of TG.
TGCV is at high risk for skeletal myopathy and heart dysfunction, and therefore premature death. Development of
therapeutic methods for TGCV is highly desirable. This study aims to discover specific molecules responsible for
TGCV pathogenesis.
Methods: To identify differentially expressed proteins in TGCV patient cells, the stable isotope labeling with amino
acids in cell culture (SILAC) method coupled with LC-MS/MS was performed using skin fibroblast cells derived from
two TGCV patients and three healthy volunteers. Altered protein expression in TGCV cells was confirmed using the
selected reaction monitoring (SRM) method. Microarray-based transcriptome analysis was simultaneously performed
to identify changes in gene expression in TGCV cells.
Results: Using SILAC proteomics, 4033 proteins were quantified, 53 of which showed significantly altered expression
in both TGCV patient cells. Twenty altered proteins were chosen and confirmed using SRM. SRM analysis successfully
quantified 14 proteins, 13 of which showed the same trend as SILAC proteomics. The altered protein expression data
set was used in Ingenuity Pathway Analysis (IPA), and significant networks were identified. Several of these proteins
have been previously implicated in lipid metabolism, while others represent new therapeutic targets or markers for
TGCV. Microarray analysis quantified 20743 transcripts, and 252 genes showed significantly altered expression in both
TGCV patient cells. Ten altered genes were chosen, 9 of which were successfully confirmed using quantitative RT-PCR.
Biological networks of altered genes were analyzed using an IPA search.
Conclusions: We performed the SILAC- and SRM-based identification-through-confirmation study using skin fibroblast
cells derived from TGCV patients, and first identified altered proteins specific for TGCV. Microarray analysis also identified
changes in gene expression. The functional networks of the altered proteins and genes are discussed. Our findings
will be exploited to elucidate the pathogenesis of TGCV and discover clinically relevant molecules for TGCV in the
near future.
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Adipose triglyceride lipase (ATGL) deficiency causes
the onset of neutral lipid storage disease with myopathy
(NLSDM), a rare genetic disorder which is transmitted as
an autosomal recessive trait [1,2]. Patients with NLSDM
have either homozygous or compound heterozygous
mutations in the ATGL gene. ATGL catalyzes the rate-
limiting step in the hydrolysis of TG stored in lipid
droplets [3,4]. ATGL deficiency is characterized by the
presence of intracellular triglyceride (TG) deposition in
most tissues, including leukocytes (Jordans’ anomaly),
skeletal muscles and the heart [1,2]. Clinically, the patients
reported so far show primarily skeletal muscle weakness
associated with myopathy, with highly elevated creatine
kinase levels, and show cardiomyopathy usually observed
at later stages of the disease [2,5].
One of the NLSDM phenotypes, discovered in Japan,
shows massive TG accumulation in both the coronary
artery and myocardium, resulting in severe heart failure.
This symptom has been designated “Triglyceride deposit
cardiomyovasculopathy (TGCV)” [6,7]. Cardiomyopathy
is lethal in patients with TGCV and necessitates cardiac
transplantation; thus, therapeutic methods for reducing the
burden on patients with this intractable disease are highly
desirable. In addition, sensitive noninvasive biomarkers are
needed for monitoring the therapeutic response rather
than diagnostic biomarkers for detecting this disease.
A clear understanding of the pathogenesis of TGCV is
essential to exploit the therapeutic methods. However, the
molecular nature of TGCV remains unknown to date.
As proteins are almost always the effectors of cellular
functions, the use of proteomic approaches to decipher
the molecular basis of diseases might offer new insight.
Therefore, in this study, we performed proteomic analysis
to examine differentially expressed proteins in TGCV
patient cells. We employed the stable isotope labeling with
amino acids in cell culture (SILAC) method coupled with
LC-MS/MS [8] and performed large-scale quantitative
proteomic analysis.
The list of differentially expressed proteins obtained by
comprehensive quantitative analysis needs to be validated,
but this step is an expensive and time-consuming process
requiring a pre-existing antibody. A more recent mass
spectrometry-based technique called selected/multiple
reaction monitoring (SRM/MRM) is a useful method for
the validation of proteins without antibodies [9]. In this
study, we confirmed differentially expressed proteins
identified by SILAC proteomics using SRM/MRM. As
a result, we identified for the first time differentially
expressed proteins between TGCV patient and healthy
volunteer cells. Our identified proteins will be useful
for elucidation of the pathogenesis of TGCV and the
exploitation of therapeutic methods for TGCV in the
future.Methods
Cell culture
Skin fibroblast cells were isolated from the skin of two
TGCV patients in the Department of Cardiovascular
Medicine, Osaka University Graduate School of Medicine,
Japan. The local ethics committee approved the study
and informed consent was obtained from the donors.
Cells were cultured in Iscove’s modified Dulbecco’s
medium (IMDM) supplemented with 10% fetal bovine
serum (FBS; Invitrogen, Carlsbad, CA, USA) and peni-
cillin/streptomycin (100 IU/ml). For SILAC experiments,
Dulbecco's modified Eagle’s medium without L-arginie
and L-lysine (Invitrogen) was supplemented with dialyzed
FBS (Invitrogen). The medium was then divided into three
portions and supplemented with 13C6,
15 N4 L-arginine
and 13C6,
15 N2 L-lysine or
13C6 L-arginine and
4,4,5,5D4
L-lysine or normal L-arginine and L-lysine, to produce
“heavy” or “medium” or “light” SILAC medium, respectively.
All isotopes labeled L-arginine and L-lysine were purchased
from Cambridge Isotope Laboratories (Tewksbury, MA,
USA). Skin fibroblast cells were grown in SILAC medium
for at least 6 doubling times to ensure that the amino
acids had been fully incorporated.
Oil red O lipid staining
Cells were cultured on chamber slides (BD Biosciences,
San Jose, CA, USA). The staining solution was prepared
by dissolving 0.5 g Oil Red O powder (Sigma-Aldrich,
St Louis, MO, USA) in 100 ml isopropanol, followed by
1:1 dilution with distilled water. Then, the solution was
allowed to stand for 10 min before it was filtered through
filter paper. The cells were washed in PBS, fixed with 10%
formalin at room temperature for 10 min, and stained
with Oil Red O at room temperature for 20 min. Samples
were washed with distilled water and counterstained with
Mayer's hematoxylin (Wako Pure Chemical Industries,
Osaka, Japan) for 2 min.
Preparation of protein samples, 1-D SDS-PAGE separation
and in-gel trypsin digestion
Cells were scraped into ice-cold RIPA buffer containing
50 mM Tris–HCl, pH 8.0, 150 mM NaCl, 1% Nonidet
P-40, 0.5% sodium deoxycholate, 0.1% SDS, with 1 ×
protease inhibitor, compete Mini (Roche Applied Science,
Indianapolis, IN, USA) and agitated at 4°C for 30 min.
After centrifugation at 14000 rpm at 4°C for 20 min,
lysates were collected and protein concentrations were
determined using a DC Protein Assay (Bio-Rad, Hercules,
CA, USA). Equal amounts (in weight) of lysates from
three light (Arg0, Lys0) labeled control cells were pooled
to generate the control, and then lysates of three labeled
types, light (Arg0, Lys0), medium (Arg6, Lys4) and heavy
(Arg10, Lys8), were mixed in equal amount (in weight). A
100 μg sample of mixed proteins was separated by SDS-
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Bands were visualized with Gels Simply Blue Safe Stain
(Invitrogen) and lanes were sliced into 46 sections. After
distaining with 50% ethanol in 50 mM ammonium
bicarbonate (ABC), proteins in gel pieces were reduced
with 10 mM DTT in ABC and alkylated by 50 mM
iodoacetamide in ABC. After gel dehydration with
100% ethanol, the gel pieces were covered with
approximately ~40 μl of 12.5 μg/mL trypsin in ABC
and in-gel digestion was performed at 37°C for 16 h.
Peptides were extracted from gels with 3% trifluoroacetic
acid (TFA), 30% acetonitrile (ACN) and then 100% ACN.
The resulting peptide mixtures were dried and resolved
with 0.1% TFA and 2% ACN, and desalted using C18
stage Tips [10].NanoLC-MS/MS
NanoLC-MS/MS analysis was conducted using an LTQ-
Orbitrap Velos mass spectrometer (Thermo Fisher Scien-
tific, Bremen, Germany) equipped with a nanoLC interface
(AMR, Tokyo, Japan), a nano HPLC system (Paradigm
MS2; Michrom Bioresources, Auburn, CA, USA), and
an HTC-PAL autosampler (CTC Analytics, Zwingen,
Switzerland). L-column2 C18 particles (Chemicals Evalu-
ation and Research Institute, Kurume, Japan) were packed
into a self-pulled needle (200 mm length × 100 μm inner
diameter) using a Nanobaume capillary column packer
(Western Fluids Engineering, Wildomar, CA, USA). The
mobile phases consisted of (A) 0.1% formic acid and
2% ACN and (B) 0.1% formic acid and 90% ACN. The
peptides dissolved in 2% ACN and 0.1% TFA were
loaded onto a trap column (0.3 × 5 mm, L-column ODS;
CERI, Japan). The nanoLC gradient was delivered at
500 nl/min and consisted of a linear gradient of mobile
phase B developed from 5 to 35% in 135 min. A spray
voltage of 2000 V was applied.Data acquisition with LTQ-Orbitrap Velos
Full MS scans were performed in the orbitrap mass
analyzer of LTQ-Orbitrap Velos (scan range 350–1500 m/z,
with 30 K full width at half maximum (FWHM) reso-
lution at 400 m/z). In MS scans, the 10 most intense
precursor ions were selected for MS/MS scans with
the LTQ-Orbitrap Velos. The dynamic exclusion option
was implemented with a repeat count of 1 and exclu-
sion duration of 60 s. This was followed by collision-
induced dissociation (CID) MS/MS scans of the selected
ions performed in the linear ion trap mass analyzer.
The values of automated gain control (AGC) were
set to 1.00 × 106 for full MS and 1.00 × 104 for CID
MS/MS. Normalized collision energy values were set
to 35%.Protein identification and quantification using
MaxQuant software
The resulting mass spectra were analyzed using MaxQuant
Software (version 1.2.2.5) [11]. In short, raw MS files were
loaded directly into MaxQuant, and identification and
quantitation of individual peptides were generated in
protein groups. The MaxQuant searches were executed
using the International Protein Index (IPI) human protein
database (version 3.67, 87302 forward and 87302 reverse
protein sequences). All entries were filtered using a false
positive rate of 1%. The following search parameters were
used: two missed cleavages permitted, carbamidometh-
ylation on cysteine fixed modification, and oxidation
(methionine) and acetyl (N-terminus proteins) variable
modifications. The mass tolerances for precursor ions
and fragment ions were 20 ppm and 0.5 Da, respectively.
Quantification of proteins was based on the normalized
heavy/light (H/L) and medium/light (M/L) ratios as deter-
mined by MaxQuant.
Stable isotope-labeled peptides
Proteotypic peptides were chosen based on SILAC pro-
teomics data. For SRM/MRM analysis of the 20 target
proteins, 42 stable isotope-labeled peptides (SI-peptides,
crude peptide: approximately 50% peptide purity and
>99% isotope purity; Greiner Bio One, Frickenhausen,
Germany) were synthesized. SI-peptides had isotope-
labeled lysine or arginine at their C-terminus. Each
SI-peptide was dissolved in distilled 40% ACN and
0.1% TFA, and stored at −80°C.
Creation of SRM/MRM transition list using SI-peptides
The mixture of SI-peptides was analyzed by LC-MS/MS
using LTQ-Orbitrap XL (CID mode), and an msf file
was generated using Proteome Discoverer and Mascot.
The msf file was opened with Pinpoint software (version
2.3.0; Thermo Fisher Scientific), and a list of MS/MS
fragment ions derived from SI-peptides was generated.
Four MS/MS fragment ions were selected for SRM/
MRM transitions of each targeted peptide based on the
following criteria: y-ion series, strong ion intensity and
at least 2 amino acids in length.
Optimization and operation of SRM/MRM method
SRM/MRM methods for each SI-peptide were created
by Pinpoint 1.0, which included SRM/MRM transition
lists and the instrument method with the following
parameters: scan width of 0.002 m/z, Q1 resolution of
0.7 FWHM, cycle time of 1 s, and gas pressure of 1.8
mTorr. The SI-peptide mixture was analyzed by LC-
SRM/MRM on the TSQ-Vantage triple quadruple mass
spectrometer (Thermo Fisher Scientific) equipped with
the parameters mentioned above. The nanoLC gradient
was delivered at 500 nl/min and a spray voltage of 1900–
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were performed to establish the retention time window
(±2 min) for each peptide ion and optimize the collision
energy for each transition. Four transitions were chosen
for each peptide and all fragment ions were y-ions. When
possible, two peptides were used per protein and all SRM/
MRM analyses were run in duplicate. For SRM/MRM
analyses, proteins were prepared as follows. Skin fibroblast
cells cultured in normal IMDM medium were harvested,
and proteolytic digestion were performed by a phase-
transfer surfactant (PTS) protocol using an MPEX PTS
reagent kit (GL Sciences, Tokyo, Japan) [12]. Briefly, pellets
were lysed with PTS B buffer followed by sonication for
5 min using a Bioruptor sonicator (Cosmo Bio, Tokyo,
Japan). Lysed proteins were reduced with 10 mM DTT,
alkylated with 50 mM iodoacetamide and sequentially
digested by 1:100 (w/w) trypsin for 16 h at 37°C. An
equal volume of ethylacetate was added to the digested
samples, and the mixtures were acidified by 1% TFA
followed by vortexing to transfer the detergents to the
organic phase. After centrifugation, the aqueous phase
containing peptides was collected. The resulting peptide
mixtures were desalted using C18 stage Tips and resolved
with 0.1% TFA and 2% ACN. Two micrograms of digested
sample were transferred to a new tube and the SI-peptide
mixture was added. The amount of SI-peptide was opti-
mized to achieve similar ion intensity to the corre-
sponding endogenous peptide, if possible. Samples were
analyzed by LC-SRM/MRM on the TSQ-Vantage using
the optimized SRM/MRM method.SRM/MRM data analysis
SRM/MRM data were processed using Pinpoint 1.0.
The peak area in the chromatogram of each SRM/MRM
transition was calculated, and the values of endogenous
targeted peptides were normalized to those of the
corresponding SI-peptides. When the transition pro-
file was different between endogenous peptides and
SI-peptides, the transition was excluded from the quan-
tification process. The different transition profile might
have been caused by the detection of untargeted peptides.
In addition, transitions having signal-to-noise ratios
(S/N) of <10 were discarded from this study. In such
cases, only peptides having more than one transition
were used.
Protein accession numbers identified by SILAC prote-
omics analysis and their corresponding fold changes were
imported into Ingenuity Pathway Analysis (IPA) software
(Ingenuity Systems, Redwood City, CA, USA, www.in-
genuity.com) for network and functional analysis. IPA
is web-based software that constructs protein interaction
networks in silico based upon published associations that
have been collated from the literature.Microarray analysis
Skin fibroblast cells derived from two TGCV patient cells
and two control cells (LC1, LC2, control1 and control2)
were cultured in SILAC medium. Cells were harvested,
and total RNA was isolated using a QIA shredder (Qiagen,
Valencia, CA, USA) and an RNeasy Mini Kit (Qiagen)
according to the manufacturer’s instructions. The quantity
and purity of RNA were evaluated using a NanoDrop
(Nanodrop Technologies, Wilmington, DE, USA) and an
Agilent 2100 Bioanalyzer (Agilent Biotechnologies, Santa
Clara, CA, USA). RNA from two control cells was equally
mixed prior to array analysis. Analysis using Human
Genome U133 Plus 2.0 microarray (Affymetrix, Santa
Clara, CA, USA) was performed according to the standard
Affymetrix protocol. Briefly, total RNA was reverse-
transcribed into complementary DNA (cDNA) and cDNA
was in vitro transcribed to biotinylated RNA. After
fragmentation, 12.5 μg biotinylated RNA was hybrid-
ized overnight to the array, and then arrays were washed,
stained with streptavidin–phycoerythrin and scanned
using a GeneChip 3000 7G scanner (Affymetrix). The
acquisition and initial quantification of array images
were conducted using GeneChip Command Console
Software (Affymetrix), then data were analyzed by
GeneSpring GX Software (Affymetrix). We used present
and absent call filtering to determine which transcripts
were able to be considered accurately measured, which
is a standard method for microarray analysis [13].
Real-time reverse transcription PCR
Total RNA was isolated from skin fibroblast cells using
the same method as described above, except that cells
were cultured in normal medium. Complementary DNA
was synthesized using the First Strand cDNA Synthesis
Kit for RT-PCR (AMV) (Roche Applied Science). Real-
time reverse transcription (RT) -PCR was performed using
the Power SYBR Green PCR Master Mix (Applied Bio-
systems, Foster City, CA, USA) and ABI Prism 7900HT




3′ (forward) and 5′-ATGAAGGCCTTCATCAGCTCG-3′
(reverse); PLA2G4A, 5′-ACCCAAGAATCCTGATATG
GAG-3′ (forward) and 5′-CCTGGAGCCTTGTACTTTC
TG-3′ (reverse); FLG, 5′-TAGACACTCTCAGCACGGA
AGTG-3′ (forward) and 5′-CCTGGGTCCTTATTAATA
TACG-3′ (reverse); FBL2, 5′-GGGAACTGTGGGCTGT
ACTAC-3′ (forward) and 5′-AAATCCCATTACGGACA
CCTCT-3′ (reverse); RAB27B, 5′-CCTACCAGATCAGA
GGGAAGTC-3′ (forward) and 5′-CATTCTGTCCAGTT
GCTGCAC-3′ (reverse); MC4R, 5′-AGGTGCCAATATG
AAGGGAGCG-3′ (forward) and 5′-GGATTCTGAGGA
CAAGAGATGTAG-3′ (reverse); SLC16A6, 5′-TCAGAG
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GCTGTAGATCTTAC-3′ (reverse); TNFRSF21, 5′-TCTC
CGCTGTGACTCTACATC-3′ (forward) and 5′-TACCT
GCCGCAACACTGTGTC-3′ (reverse); NCAM1, 5′-GA
AAGATGAGTCCAAGGAGCC-3′ (forward) and 5′-TCC
GTCAGTGGCGTGGTCTCG-3′ (reverse); PLIN2, 5′-TT
GGATATGATGATACTGATG-3′ (forward) and 5′-ACG
TGGTCTGGAGCTGCTGAG-3′ (reverse); RPS18, 5′-TT
TGCGAGTACTCAACACCAAC-3′ (forward) and 5′-AG
CATATCTTCGGCCCACACC-3′ (reverse). The rela-
tive mRNA levels of each gene were normalized to
RPS18 expression.
Results
Identification of proteins differentially expressed in TGCV
patient cells
We have applied a quantitative proteomics approach using
skin fibroblast cells to identify proteins differentially
expressed between TGCV patients and healthy volunteers
(control). Tissue samples from primary lesions such as
skeletal and cardiac muscles would have been ideal sources
for our analyses [7]; however, they were unavailable. Thus,
we selected skin fibroblast cells to perform proteomic
analysis for two reasons. First, TGCV is a substantially
rare disease and the only patient-derived cells found so
far to act as proteomic resources are two fibroblasts.
Second, patient-derived skin fibroblast cells have been
utilized by several groups to study the features of
NLSDM and showed intracellular deposition of lipid
droplets [1,5]. Indeed, we confirmed that TGCV patient
cells accumulated lipid droplets as described later
(Figure 1B).
SILAC is a metabolic protein labeling method that
employs isotopic variants of amino acids added to the
growth medium [8]. Most commonly, different populations
of cells are grown in medium containing distinct forms
of both arginine (Arg) and lysine (Lys). SILAC analysis
facilitates the relative quantification of small changes in
protein abundance in cells and allows for the discovery
of novel cellular pathways that are altered in disease
progression.
In this study, we used the triple SILAC method in
which two patient cells were labeled with distinct isotopic
forms of amino acids. A schematic experimental design is
shown in Figure 1A. In short, fibroblasts derived from
two different patients, LC1 and LC2, were grown in
medium (M) and heavy (H), respectively, and three
control fibroblasts (control1, control2 and control3)
were independently grown in light (L). Proteins extracted
from the three control cells were mixed at the same
protein concentration and used as a control for proteomic
analysis. Then, proteins from the three labeled cell popula-
tions (LC1-M, LC2-H, and control -L) were mixed equally,
followed by separation with SDS-PAGE. After separatingthe proteins, the gel was excised into 46 sections and
proteins were in-gel digested with trypsin, extracted
from gel pieces and analyzed by LC-MS/MS.
It was not immediately clear whether the dialyzed FBS,
commonly used for SILAC labeling as described in the
Methods section, would maintain the lipid deposition of
patient cells. Thus, we examined whether the labeling
procedure affected the lipid droplet deposition of patient
cells in SILAC medium. After more than six doublings,
which were sufficient for complete incorporation of the
isotopic form of amino acids, patient cells remained in
the lipid droplet deposition state, as demonstrated by
Oil Red O staining (Figure 1B).
We were able to identify 4570 proteins with a false
discovery rate (FDR) for protein identification of 1%,
determined by searching a reverse database, and among
the identified proteins, 4033 could be quantified. A list
of all identified proteins is presented in Additional file 1:
Table S1.
Prior to analyzing differentially expressed proteins, we
plotted log2 transformed M/L (LC1/control) and H/L
(LC2/control) ratios of all quantified proteins. Histograms
of both LC1 and LC2 ratios showed normal Gaussian
distribution centered around zero (Figure 2A). These
normal distributions indicated that labeling processes
by two distinct isotopic forms, M and H, did not produce
a bias. In addition, various housekeeping proteins, in-
cluding GAPDH, ACTB, PPIA, RPLP1, RPLP2 and RPS18,
all exhibited ratios around 1 (Figure 2B).
To find differentially expressed proteins in patient
cells, we determined the cut-off values for LC1 and LC2
data sets. The cut-off value of 1.5 for both LC1 and LC2
was selected, because 1.5 was approximately the mean
plus two standard deviations (Figure 2A, lower panel). A
logarithmic (log2) plot of the SILAC ratios H/L (X-axis)
and M/L (Y-axis) for each quantified protein allows the
unbiased identification of proteins that are specifically
differentially expressed in patient cells (Figure 2C). Almost
all proteins identified had ratios of around 1:1, and thus
clustered around the intersection of the X- and Y-axes.
Proteins over-expressed in both LC1 and LC2 have a
high ratio of both M/L and H/L and could therefore be
identified as outliers in the top right quadrant. In contrast,
proteins under-expressed in both cells have a low ratio
of both M/L and H/L and were identified as outliers in
the bottom left quadrant.
Using cut-off values (>1.5 or <0.67), 69 and 152 proteins
were found to be over- and under-expressed, respectively,
in LC1 cells, and 63 and 138 proteins were found to be
over- and under-expressed, respectively, in LC2 cells
compared to control cells (Figure 2D, upper panel). To
ensure that the observed changes of protein expression
in patient cells were the result of TGCV, we considered
stringent criteria. Each of the changed proteins had to
Figure 1 SILAC-based quantitative proteomics. (A) Flowchart of triple SILAC coupled with LC-MS/MS for the comparative analysis of three
distinct cell populations. (B) Oil Red O staining of SILAC-labeled skin fibroblast cells derived from TGCV patients and healthy volunteers (controls).
Characters on left and right sides of panels indicate names of patient and control cells, respectively.
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any proteins found to meet the cut-off value in one
patient cell data set but not in the other. After imple-
menting the above stringent criteria, 17 and 51 proteins
remained as over- and under-expressed, respectively, in
both patient cells.
Furthermore, we manually checked the actual identified
peptide ratios of each differentially expressed protein.
If there were only two quantified peptides, individual
peptides must have met the cut-off value (>1.5 or <0.67)
and proteins found not to meet this criteria were
discarded. Finally, 17 and 36 proteins remained as
over- and under-expressed, respectively (Figure 2D,
lower panel). A summary of SILAC proteomics is shown
in Figure 2E. The quantification results for all the dif-
ferentially expressed proteins measured in LC1 and
LC2 cells are summarized in Table 1.Function and network analysis of identified proteins
To reveal significant networks relevant to the pathogen-
esis of TGCV, we next imported the identified proteins
list into IPA. First, we focused on “Lipid Metabolism” in
the functional distribution of identified proteins. Figure 3
shows the bio-functions of three data sets. Using thedata set for all altered proteins, IPA identified “Lipid
Metabolism” with higher significance, which ranked as a
top group (Figure 3A). This result indicated that lipid
metabolism-related proteins were specifically regulated
in TGCV patient cells and our proteome analysis was not
biased under experimental conditions. When the under-
expressed proteins set was used, IPA also identified similar
functions to those of all altered proteins and “Lipid
Metabolism” was also ranked as a top group (Figure 3B).
Therefore, under-expressed proteins might represent a
functional change in TGCV patient cells. In contrast,
when the over-expressed proteins set was used, IPA
indicated different functions and “Lipid Metabolism”
was ranked lower (Figure 3C).
Furthermore, we focused on category-specific bio-
functions and discovered that “Lipid Metabolism” was
top-ranked in Molecular and Cellular Functions in both
all altered proteins and the under-expressed proteins
sets (Figure 3D and E). Thus, it appeared that “Lipid
Metabolism” might be entirely influenced by a loss-of-
function mutation of ATGL. With regard to individual
functions in “Lipid Metabolism”, “lipid synthesis” was found
to be the most significant (P = 5.76E-06) and repressed
(activation Z score = −2.02) function, which consisted
of ACOX2, AKR1B1, DHCR24, DPP4, FABP3, FADS2,
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Figure 2 Statistical analysis of SILAC data of two patient cells. (A) Upper panels, log2 distributions of Medium (M)/Light (L) and Heavy (H)/
Light (L) ratios of proteins quantified in SILAC analysis. Dashed lines represented log2 transformed cut-off values (>1.5, <0.67). Lower panel, statistical
summary of ratios of two patient cells. (B) Ratios of various housekeeping proteins identified in SILAC analysis. (C) Scatter plot of log2 transformed
patient cells/control cells ratios. X- and Y- axes represent log2 transformed M/L and H/L ratios, respectively, as indicated in the graph. (D) Upper panels,
Venn diagrams show the number of overlapping altered proteins between the two patient cells. Lower panel, if there were only two quantified
peptides, individual peptides must have met the cut-off value (>1.5 or <0.67) and proteins found not to meet this criteria were discarded. “Manual
check-passed” represents remaining proteins after implementing the above criteria. (E) Summary of quantitative proteomics.
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which have been previously reported to be associated with
metabolic disease, as discussed later (Table 2) [14-23]. It
should be noted that the function “Concentration of triac-
ylglycerol” was identified in the all altered proteins data
set and activated (activation Z score = 1.45) (Table 2).
This might have been mostly owing to the presence of
PLIN2, a lipid droplet maintenance protein described
later. These results indicated that our proteomics analysiscould usefully identify proteins specific for lipid metabol-
ism aberration.
Next, we systematically evaluated the functions of
identified proteins by investigating the results of network
analysis. Five networks were found to be significant
using the all altered proteins data set, of which two net-
works were highly significant, with scores greater than
30 (Additional file 2: Table S2A). The major functions of
network1 were “Dermatological Diseases and Conditions”,
Table 1 Differentially expressed proteins in TGCV patient cells
Protein description Symbol ID Ratio
LC1 (M/L) LC2 (H/L) Ave
Over-expressed proteins
Filaggrin FLG IPI00026256 3.66 12.67 8.17
Collagen triple helix repeat containing 1 CTHRC1 IPI00060423 3.86 2.25 3.06
Aldehyde dehydrogenase 1 family, member B1 ALDH1B1 IPI00103467 1.51 3.28 2.4
Ribosomal protein S4, Y-linked 1 RPS4Y1 IPI00302740 2.17 2.54 2.36
Integrin, alpha 11 ITGA11 IPI00215613 1.71 2.73 2.22
Perilipin 2 PLIN2 IPI00293307 2.47 1.87 2.17
Molybdenum cofactor sulfurase MOCOS IPI00304895 2.48 1.72 2.1
DEAD (Asp-Glu-Ala-Asp) box polypeptide 3, Y-linked DDX3Y IPI00293616 1.94 2.14 2.04
LIM and cysteine-rich domains 1 LMCD1 IPI00303258 2.02 2.05 2.04
Integrin, alpha 6 ITGA6 IPI00010697 1.69 2.23 1.96
Nicotinamide N-methyltransferase NNMT IPI00027681 1.78 1.81 1.8
Glutamine-fructose-6-phosphate transaminase 2 GFPT2 IPI00216159 1.85 1.6 1.73
Membrane metallo-endopeptidase MME IPI00247063 1.64 1.77 1.71
Met proto-oncogene (hepatocyte growth factor receptor) MET IPI00294528 1.67 1.7 1.69
BAI1-associated protein 2 BAIAP2 IPI00299088 1.73 1.62 1.68
TSC22 domain family, member 2 TSC22D2 IPI00477806 1.68 1.57 1.63
von Willebrand factor A domain containing 8 VWA8 IPI00900366 1.66 1.59 1.63
Under-expressed proteins
Mitochondrial ribosomal protein S28 MRPS28 IPI00795922 0.24 0.36 0.3
Collagen, type XVIII, alpha 1 COL18A1 IPI00783931 0.34 0.26 0.3
Armadillo repeat containing 9 ARMC9 IPI00829927 0.29 0.34 0.32
Fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor) FABP3 IPI00219684 0.4 0.26 0.33
Transient receptor potential cation channel, subfamily V, member 2 TRPV2 IPI00183666 0.16 0.51 0.34
Collagen, type VIII, alpha 1 COL8A1 IPI00942464 0.35 0.36 0.36
5'-nucleotidase domain containing 3 NT5DC3 IPI00465170 0.4 0.34 0.37
Gremlin 1, DAN family BMP antagonist GREM1 IPI00298476 0.36 0.39 0.38
Dipeptidyl-peptidase 4 DPP4 IPI00018953 0.4 0.39 0.4
EH-domain containing 3 EHD3 IPI00021458 0.33 0.47 0.4
Cellular retinoic acid binding protein 2 CRABP2 IPI00216088 0.49 0.34 0.42
Aldehyde dehydrogenase 3 family, member A2 ALDH3A2 IPI00394758 0.55 0.38 0.47
Tubulin, alpha 4a TUBA4A IPI00007750 0.43 0.51 0.47
Prostaglandin-endoperoxide synthase 1 (prostaglandin G/H synthase and cyclooxygenase) PTGS1 IPI00298267 0.65 0.32 0.49
Peroxiredoxin 6 PRDX6 IPI00220301 0.44 0.54 0.49
Argininosuccinate synthase 1 ASS1 IPI00020632 0.44 0.57 0.51
Nudix (nucleoside diphosphate linked moiety X)-type motif 2 NUDT2 IPI00221231 0.54 0.48 0.51
Fatty acid desaturase 2 FADS2 IPI00183786 0.47 0.56 0.52
Collagen, type VI, alpha 3 COL6A3 IPI00072917 0.65 0.38 0.52
Opioid growth factor receptor OGFR IPI00021537 0.53 0.5 0.52
Sulfide quinone reductase-like (yeast) SQRDL IPI00009634 0.58 0.46 0.52
Farnesyl-diphosphate farnesyltransferase 1 FDFT1 IPI00020944 0.45 0.61 0.53
Acyl-CoA oxidase 2, branched chain ACOX2 IPI00293125 0.61 0.46 0.54
Phosphodiesterase 1C, calmodulin-dependent 70 kDa PDE1C IPI00028928 0.53 0.54 0.54
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Table 1 Differentially expressed proteins in TGCV patient cells (Continued)
NME/NM23 nucleoside diphosphate kinase 3 NME3 IPI00012315 0.65 0.44 0.55
Laminin, beta 1 LAMB1 IPI00013976 0.59 0.5 0.55
Aldo-keto reductase family 1, member B1 (aldose reductase) AKR1B1 IPI00413641 0.48 0.64 0.56
Chondroitin sulfate proteoglycan 4 CSPG4 IPI00019157 0.65 0.48 0.57
Glycoprotein (transmembrane) nmb GPNMB IPI00470529 0.6 0.53 0.57
Tweety homolog 3 (Drosophila) TTYH3 IPI00749429 0.53 0.63 0.58
S100 calcium binding protein A4 S100A4 IPI00032313 0.54 0.62 0.58
Paraoxonase 2 PON2 IPI00290945 0.51 0.65 0.58
24-dehydrocholesterol reductase DHCR24 IPI00016703 0.63 0.57 0.6
Potassium channel tetramerisation domain containing 12 KCTD12 IPI00060715 0.65 0.57 0.61
Mucosa associated lymphoid tissue lymphoma translocation gene 1 MALT1 IPI00009540 0.66 0.61 0.64
Phospholipase C, delta 3 PLCD3 IPI00152701 0.64 0.67 0.66
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http://www.ojrd.com/content/8/1/197“Cancer” and “Renal Urological System Development and
Function”. Specifically, the top function, “Dermatological
Diseases and Conditions”, was represented by burn
which was the most significant bio-function (P = 4.31E-06)
(Additional file 2: Table S2B). This bio-function consisted
of COL18A1, COL6A3, COL8A1 and PTGS1, most of
which have been previously described to be associated
with connective tissue function and structure (Additional
file 2: Table S2B) [24-26]. With regard to under-expressed
proteins, the major functions of network1 were “Der-
matological Diseases and Conditions”, “Gastrointestinal
Disease” and “Organismal Injury and Abnormalities”
(Additional file 2: Table S2C and D). Similar to the all
altered proteins data set, assigned proteins were involved
in connective tissue function.
On the other hand, using only the over-expressed
proteins data set, IPA identified one network with a score
greater than 30. Major functions of this network were
“Cell Morphology”, “Cellular Development” and “Cancer”,
which were not uncommon results from this sort of
analysis. It seemed that this result is mostly influenced
by only a few proteins, due to the relatively low number
of over-expressed proteins. These results were in good
agreement with the above-mentioned global functional
distribution (Figure 3A, B and C).
Confirmation of differentially expressed proteins using
SRM/MRM analysis
To ensure that the difference in protein expression
between TGCV patient cells and control cells results
from TGCV-specific processes, we performed to confirm
the differentially expressed proteins by SRM/MRM analysis
using fibroblast cell lysates cultured in normal medium.
For SRM/MRM analysis, the top 10 over- and under-
expressed proteins were selected. Target peptides for
measurement were chosen using the criteria below.
Peptides were unique proteotypic peptide sequences(typically 7–20 amino acids) based on the results obtained
from shotgun proteomics and did not possess methionine
in order to avoid partial oxidation. When possible, two
peptides were used per protein. Finally, we selected 42
peptides representing 20 differentially expressed pro-
teins. Complete information (so-called transition list)
about the selected peptides is presented in Additional
file 3: Table S3.
Whole cell lysates of fibroblast cells were digested by
trypsin and monitored by SRM/MRM analysis in duplicate.
Consequently, SRM/MRM analysis successfully quantified
7 of over-expressed and 7 of under-expressed proteins
(Figure 4). Among them, 13 proteins showed a trend in the
same direction, despite a modest change under different
cell conditions (Figure 4A and B). In addition, we focused
on 2 proteins, PLIN2 and CTHRC1, because these proteins
were possible biomarker candidates in the context of lipid
metabolism. Therefore, one more peptide was selected to
confirm the difference. CTHRC1, which has been reported
to be involved in lipid metabolism [27], successfully showed
apparent changes in all three target peptides (Figure 4A and
C). PLIN2, which has been reported to be involved in the
maintenance of lipid droplets [22,28], also showed apparent
changes in all three target peptides (Figure 4A and D).
Quantitative transcriptomic analysis of TGCV patient cells
To address the relationship of protein expression levels
with transcript levels, we performed oligonucleotide micro-
array analysis using Affymetrix microarrays of Human
Genome U133 Plus 2.0. A total of 26780 mRNA species
were quantified, of which 20743 were deemed “present”
in all three RNA samples. A list of 20743 transcripts is
presented in Additional file 4: Table S4. Histograms of
both LC1 and LC2 log2 ratios showed normal distribution
centered at zero, similar to proteome analysis (Additional
file 5: Figure S1A). These normal distributions also indi-
cated that most transcript levels were unaffected by
AB
C
Function p-value # Molecules
1 Renal and Urological System Development and Function 1.76E-06 10
2 Tissue Morphology 2.66E-06 12
3 Dermatological Diseases and Conditions 4.37E-06 14
4 Gastrointestinal Disease 4.37E-06 21
5 Organismal Injury and Abnormalities 4.37E-06 11
6 Lipid Metabolism 5.27E-06 17
7 Small Molecule Biochemistry 5.27E-06 23
8 Cancer 5.64E-06 34
9 Cellular Compromise 1.33E-05 8
10 Organ Morphology 1.56E-05 10
Function p-value # Molecules
1 Dermatological Diseases and Conditions 5.52E-07 11
2 Gastrointestinal Disease 5.52E-07 15
3 Organismal Injury and Abnormalities 5.52E-07 9
4 Organ Morphology 9.16E-07 10
5 Renal and Urological System Development and Function 9.16E-07 7
6 Lipid Metabolism 3.68E-06 14
7 Small Molecule Biochemistry 3.68E-06 18
8 Cell Morphology 1.07E-05 7
9 Molecular Transport 1.09E-05 11
10 Tissue Morphology 3.73E-05 8
Function p-value # Molecules
1 Cell Morphology 1.38E-05 6
2 Cellular Development 1.38E-05 6
3 Connective Tissue Development and Function 9.32E-05 4
4 Cancer 3.70E-04 14
5 Cellular Movement 3.70E-04 4
6 Tumor Morphology 3.70E-04 3
7 Cellular Growth and Proliferation 4.80E-04 3
8 Skeletal and Muscular System Development and Function 4.80E-04 4
9 Cell Cycle 9.91E-04 1
10 Cell Death and Survival 9.91E-04 2
Function p-value # Molecules
1 Lipid Metabolism 5.27E-06 17
2 Small Molecule Biochemistry 5.27E-06 23
3 Cellular Compromise 1.33E-05 8
4 Cell Morphology 3.67E-05 11
5 Cellular Growth and Proliferation 9.06E-05 26
Function p-value # Molecules
1 Lipid Metabolism 3.68E-06 14
2 Small Molecule Biochemistry 3.68E-06 18
3 Cell Morphology 1.07E-05 7
4 Molecular Transport 1.09E-05 11
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Figure 3 Top bio-functions of identified proteins in SILAC proteomic analysis. Functions are generated by IPA analysis and displayed
according to statistical significance values. (A-C) Top 10 global functions identified by three data sets. (A) Functions of all differentially expressed
proteins in TGCV patient cells. (B) Functions of under-expressed proteins in TGCV patient cells. (C) Functions of over-expressed proteins in TGCV
patient cells. (D) Left panel, individual functions assigned in Molecular and Cellular Functions category by using all differentially expressed proteins
in TGCV patient cells. Right panel, histogram according to p-values described in left panel. (E) Individual functions assigned in Molecular and
Cellular Functions category using under-expressed proteins, the same format as described in (D).
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http://www.ojrd.com/content/8/1/197labeling processes by two distinct isotopic forms of
amino acids. In addition, various housekeeping genes,
including GAPDH, ACTB, TBP, PPIA, RPS18, B2M, RPLP1
and RPLP2, all exhibited ratios around 1 (Additional file 6:
Table S5).
A logarithmic (log2) plot of ratios LC1/control (X-axis)
and LC2/control (Y-axis) for each quantified gene indicatesthe unbiased identification of genes that are specifically
differentially expressed in patient cells (Additional file 5:
Figure S1B). Although almost all genes identified had
ratios of around 1:1, the scatter plot at transcription levels
showed dispersion of the points around the regression
line (R2 = 0.323) compared with that of protein levels.
Transcriptomic analysis tends to show differences
Table 2 Individual functions and identified molecules in “Lipid Metabolism” in differentially expressed proteins in TGCV cells
Bio-functions Functions annotation p-value Activation z-score Molecules Number of molecules
Lipid metabolism Synthesis of lipid 5.27E-06 −2.021 ACOX2, AKR1B, DHCR24, DPP4, FABP3, FADS2,
FDFT1, ITGA6, PLIN2, PON2, PTGS1, TRPV2
12
Lipid metabolism Concentration of lipid 9.56E-05 0.117 AKR1B1, COL18A1, CSPG4, DHCR24, FABP3,
FADS2, FDFT1, PLIN2, PON2, PRDX6, PTGS1
11
Lipid metabolism Concentration of fatty acid 2.53E-04 −0.85 AKR1B1,FABP3,FADS2,PON2,PRDX6,PTGS1 6
Lipid metabolism Quantity of lipid peroxide 8.88E-04 PON2,PRDX6 2
Lipid metabolism Conversion of lipid 1.13E-03 −1.091 DHCR24,MET,PRDX6,PTGS1 4
Lipid metabolism Concentration of arachidonic acid 1.59E-03 FADS2,PTGS1 2
Lipid metabolism Transport of long chain fatty acid 2.49E-03 FABP3,PLIN2 2
Lipid metabolism Concentration of triacylglycerol 2.62E-03 1.446 AKR1B1,COL18A1,FADS2,PLIN2,PON2 5
Lipid metabolism Accumulation of phospholipid hydroperoxide 2.97E-03 PRDX6 1
























































































































































































































































































































































































































































































































































































































































































































































































Figure 4 (See legend on next page.)
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(See figure on previous page.)
Figure 4 SRM analysis confirms differential expression of proteins between TGCV patient and control cells. (A) Seven of top 10 over-expressed
proteins were successfully quantified in SRM analysis, showing the same trend as in SILAC proteomic analysis. (B) Seven of top 10 under-expressed proteins
were successfully quantified. These proteins showed the same trend as in SILAC proteomic analysis, except for one protein. Y-axis indicates the peak area
ratio of the endogenous peptide to SI-peptide. Protein names and target peptide sequences for SRM are indicated at the top of each graph. Symbols
represent each cell used in SRM analysis, as described in the figure. (C and D) Examples of peak groups of each peptide transition obtained in SRM analysis.
The peak areas from each chromatogram are displayed in parallel and represent detected ion intensities. Colors indicate the different transitions of each
peptide. (C) CTHRC1: Three endogenous target peptides were quantified. (D) PLIN2: Two endogenous target peptides were quantified (left and middle
panels). One peptide was not quantified due to a low signal-to-noise ratio in control1 (right panel). Target peptide sequences are indicated at the top.
Characters at the bottom indicate cell names. Analyses were run in duplicate.
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http://www.ojrd.com/content/8/1/197between patient and control cells due to a greater num-
ber of identified transcripts than proteins in proteomic
analysis. We considered a ratio of 2.0 as the cut-off for
differentially expressed genes and applied stringent
criteria similarly to proteome analysis; the changed
transcripts must have met cut-offs in both LC1 and
LC2. Among 20743 transcripts, 130 and 122 genes
remained as over- and under-expressed, respectively,
in both patient cells (Additional file 7: Table S6).
Confirmation of differentially expressed genes using
real-time RT-PCR (quantitative PCR) analysis
To further confirm the gene expression results from
array-based measurements, we performed quantitative
PCR (qPCR) using RNA isolated from cells cultured in
normal medium. We selected the top 5 over- and under-
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Figure 5 Protein and gene expression levels for the top 5 over- and u
of expression levels of top 5 over- (A) and under- (B) expressed proteins in
represents log2 transformed ratio in both proteome and transcriptome. Black
in the figure. Pair of bars on left and right of each graph represent log2 ratios
When a transcript was detected with more than one probe set, each ratio warevealed that 9 out of 10 showed the same direction as
array-based measurements (Additional file 8: Figure S2).
All five genes, highly expressed in array analysis,
showed apparently increasing RNA expression in qPCR
(Additional file 8: Figure S2A). In particular, FBN2, FGL2
and FLG showed RNA expression levels well consistent
with array-based results. On the other hand, 4 out of 5
under-expressed genes showed apparently decreasing RNA
expression in qPCR (Additional file 8: Figure S2B). These
results indicated that array analysis might achieve sufficient
analytical completeness.
Comparison of protein expression with gene
expression levels
For the top 5 over- and under-expressed proteins in
SILAC analysis, the proteomic and transcriptomic data
































nder-expressed proteins in SILAC analysis. (A and B) Comparison
SILAC analysis with those of microarray transcriptomic analysis. Y-axis
bars and gray bars indicate LC1 and LC2 cells, respectively, as indicated
of proteome and transcriptome, respectively, as indicated at the bottom.
s represented by separate pairs of bars.
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http://www.ojrd.com/content/8/1/197had consistent expression profiles between protein and
mRNA levels, even though no change of ALDH1B1 and
FABP3 was observed in only LC1 at mRNA levels.
Thus, the results of our proteomic analysis were further
supported by RNA expression levels, at least for these
proteins.
First, we focused on PLIN2 expression, which is a well-
known protein that coats lipid droplets in multiple non-
adipose tissues, as mentioned above [22]. The proteomic
and transcriptomic data for PLIN2 are shown in Figure 6A.
The gene products showed no change or less than that of
control cells at the transcriptome level (Figure 6A). These
data might be of interest for further investigation of the
role of PLIN2 in TGCV pathogenesis. Validation using
qPCR verified relatively similar expression levels between
patient cells and control cells (Figure 6C). These results
suggested that the stability of PLIN2 might increase at the
protein level when lipid droplets were developing and
revealed that posttranslational controls are important
regulators of PLIN2 functions.
Next, we examined filaggrin expression, the most ele-
vated molecule at the protein level, which is well-known
to contribute to skin barrier formation [29]. The prote-






















































Figure 6 SRM and qPCR analysis of two selected differentially expres
with that of microarray transcriptomics using the same format as described
levels but not transcript levels. (B) SRM analysis confirmed over-expression
of PLIN2 were not so different at transcript levels. Characters at the bottom ind
that of microarray transcriptomics using the same format as described in the
protein levels. (F) Quantitative PCR analysis confirmed over-expression of FLGFigure 6D. Quantitative PCR analysis confirmed the el-
evated expression of FLG mRNA in good agreement
with the proteomic and transcriptomic data (Figure 6F).
SRM/MRM also confirmed the same trend with the
proteomic data (Figure 6E). Filaggrin is of interest in the
context of the pathogenesis of TGCV and is discussed
in a later section.Function and network analysis of identified genes
We imported the differentially expressed genes list into
an IPA search. Five networks were identified using the
all altered genes data set, of which 4 networks were
highly significant with scores greater than 30 (Additional
file 9: Table S7A). The major functions of network1 were
“Connective Tissue Disorder”, “Developmental Disorder”
and “Liver Cirrhosis”. The top function included in net-
work1 was represented by COL18A1, CSPG4, FBLN1,
GATA6, LAMA1, LAMA2, MMP1, OLR1, PLA2G4a and
TGFB2, most of which have been previously reported to
be closely associated with connective tissue function and
structure (Additional file 9: Table S7B) [26,30-36]. These
results were in good agreement with the changes of con-









































































































sed proteins. (A) Comparison of PLIN2 expression in SILAC proteomics
in the legend of Figure 5. PLIN2 expression is elevated at protein
of PLIN2 at protein levels. (C) qPCR analysis confirmed that expressions
icate cell names. (D) Comparison of FLG expression in SILAC analysis with
legend of Figure 5. (E) SRM analysis confirmed over-expression of FLG at
at transcript levels. Characters at the bottom indicate cell names.
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Genetic mutations in ATGL are known causes of TGCV,
but the pathogenesis mechanism remains unclear. Here
we examined proteomic profiles of skin fibroblast cells
derived from patients to elucidate pathogenesis processes
and find clinically relevant proteins for TGCV. We identi-
fied over 4500 proteins, and specified over 50 proteins to
be differentially expressed between TGCV and healthy
control cells. To our knowledge, this is the most compre-
hensive quantitative study to date, aiming to understand
the pathogenesis mechanisms of ATGL deficiency. We
have provided a comprehensive proteome database that
is essential to discover the key molecules underlying
ATGL deficiency.
The main findings of our study are as follows. (1) Bio-
function analysis revealed that proteins associated with
“Lipid Metabolism” were affected by the cellular status
of TGCV. Those proteins, such as DPP4, PON2, PTGS1
and PLIN2, are known to be key molecules in the meta-
bolic process. (2) Network analysis revealed that the main
network of altered proteins and genes in TGCV cells was
tightly associated with connective tissue disorders. (3)
Candidate proteins responsible for TGCV pathogenesis
were discovered, such as PLIN2, CTHRC1 and FLG, and
their altered expressions were confirmed by SRM/MRM
and qPCR.
IPA analysis identified “Lipid Metabolism” as the top-
ranked bio-function of altered proteins in TGCV cells.
Proteins involved in this function are well-known key
molecules in the metabolic process, as described in the
Results section (Table 2) and are therefore candidate targets
of therapy. For example, DPP4 is a serine protease, that
specifically degrades incretin hormones; thus, its inhibitor
is considered as a useful drug for type 2 diabetes mellitus
[37]. Recently, DPP4 inhibition was also reported to
be associated with an improved cardiovascular profile,
although its precise role is still unknown [38]. PON2
possesses anti-oxidant properties, protecting cells from
oxidative stress [39] and has been suggested to exert
protection against macrophage TG accumulation and
oxidative stress [40]. PTGS1, also known as cyclooxy-
genase 1, plays a pivotal role in the biosynthesis of
prostanoids and thus regulation of PTGS1 activity has
been considered in the therapy for various diseases [23,41].
Therefore, these proteins are considerable candidates as
therapy targets for TGCV, even though their involvement
in TGCV pathogenesis is unknown.
Reduced expression of PTGS1 was identified in both
proteomic and transcriptomic analysis (Table 1 and
Additional file 7: Table S6). In addition, reduced expres-
sion of PTGS2, which is the key enzyme in prostaglandin
biosynthesis similar to PTGS1 [42], was also detected
at the transcription level (Additional file 7: Table S6).
In contrast, over-expression of PLA2G4A, which is theenzyme that releases arachidonic acid from the phospho-
lipid [43], was observed at the transcription level and
confirmed by qPCR (Additional file 7: Table S6 and
Additional file 8: Figure S2). From these results, we
speculate that aberration of the arachidonic acid cascade
may occur in TGCV cells. However, further investigation
is needed for elucidation.
IPA network analysis also revealed that the top-ranked
networks of differentially expressed proteins and genes
were tightly associated with connective tissue-related mol-
ecules (Additional file 2: Table S2 and Additional file 9:
Table S7). For example, COL18A1, COL6A3, COL8A1,
FBLN1, LAMA1, LAMA2 and CSPG4 are well-known
extracellular matrix proteins [24-26,30,31,34]. TGCV
patients showed marked characteristics, such as massive
accumulation of TG in the skeletal, heart muscles and
coronary artery. Aberration of molecules composed of
connective tissues appeared to be involved in this
symptom, but its precise role in the pathogenesis is
still unclear and awaits further investigation.
Of the top-ranked over-expressed proteins, we focused
on three proteins, PLIN2, CTHRC1 and FLG, whose
over-expression was successfully confirmed by SRM/MRM.
These proteins are interesting in the context of lipid
metabolism disorders as discussed below.
PLIN2, is well-known to play a role in the formation
of intracellular lipid droplets, and therefore to promote
neutral lipid stores, particularly in non-adipose tissues
[22]. It exhibited a 2.1-fold increase in TGCV patient cells
and was successfully confirmed in SRM/MRM analysis
(Table 1, Figure 4A and D). Straub et al. described that
PLIN2 was a general marker for a variety of human
diseases associated with lipid droplet accumulation
[28]. In this study, we showed that PLIN2 was over-
expressed in TGCV patient cells at the protein level,
which was in good agreement with previous studies in the
context of lipid storage diseases. In contrast, results from
both array and qPCR analysis indicated that PLIN2
expression did not differ at mRNA levels between
TGCV patient and control cells (Figure 6). From these
results, we suggest that PLIN2 may be stabilized at the
protein level during the progression of lipid droplets
in TGCV patient cells. A possible reason is that PLIN2
was protected from the proteolysis pathway through
the interaction with lipid droplets. However, more
studies are needed to reach a firm conclusion.
One of the top-ranked over-expressed proteins, CTHRC1,
which was 3-fold elevated in patient cells, was success-
fully confirmed in SRM/MRM analysis (Figure 4A and C).
CTHRC1 is a secreted protein that has activity to repress
collagen matrix synthesis during vascular remodeling
[44]. Therefore, it appears to be involved in the gener-
ation of atherosclerosis lesions in TGCV. Interestingly,
a recent study by Stohn et al. identified CTHRC1 as a
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effects [27]. Livers from CTHRC1 null mice accumulated
vast quantities of lipid, leading to extensive macrovesicular
steatosis. Thus, CTHRC1 is likely to have the ability to
repress the generation of lipid droplets and be over-
expressed as it reflects the deposition of TG in TGCV
patient cells. It should be noted that CTHRC1 may be
a possible candidate biomarker for TGCV as it is a
secreted protein. However, its precise role in TGCV
pathogenesis and value as a biomarker for TGCV await
further investigation of patients.
The other top-ranked over-expressed protein, FLG,
was 8-fold elevated (Table 1). FLG is a key molecule that
facilitates terminal differentiation of the epidermis and
formation of the protective skin barrier [45]. Lipid
organization is well-known to play an important role in
epidermal differentiation [46,47]. Thus, one question is
whether FLG over-expression occurs as a result of a
disorder of epidermal differentiation, which is affected
by lipid metabolism failure. However, this might be
contradictory. FLG acts as a major component in the
outer layer of the epidermis [29,45]. On the other hand,
skin fibroblast cells exist in the dermis, separated from
the epidermis by a basement membrane. Therefore, it
is unlikely that FLG over-expression in skin fibroblast
cells is a result of a disorder of epidermal differentiation.
Over-expression of FLG may rather be involved in TGCV
pathological conditions, although the contributions of
FLG to the TGCV pathogenesis process remain to be
elucidated.Conclusions
Although numerous studies have been performed to
elucidate the pathogenesis of rare diseases, few have
succeeded, mainly due to the lack of comprehensive
studies, which are difficult because the research is often
limited by ethical issues involved in the use of patient
materials. To overcome this difficulty and understand
TGCV, we performed an SILAC- and SRM/MRM-based
identification-through-confirmation study using skin fibro-
blast cells derived from two patients, which contributed
to finding clinically worthwhile proteins for TGCV. This
strategy provides rapid and comprehensive identification
of differentially expressed proteins in TGCV patient cells.
Consequently, we were able to identify and quantify
4033 proteins, 53 of which showed significantly altered
expression in TGCV patient cells. A complete quantified
proteins list is available as Additional file 1: Table S1. In
addition, a complete quantified transcripts list is available
as Additional file 4: Table S4. Our findings will be useful
to elucidate the pathogenic mechanism of TGCV and
discover clinically relevant molecules for TGCV in the
near future.Additional files
Additional file 1: Table S1. A list of identified and quantified proteins
in SILAC proteomics analysis by MaxQuant software.
Additional file 2: Table S2. Networks of differentially expressed
proteins in TGCV cells.
Additional file 3: Table S3. Sequences and SRM transitions of target
peptide for 20 proteins.
Additional file 4: Table S4. A list of identified and quantified
transcripts by Human Genome U133 Plus 2.0 array.
Additional file 5: Figure S1. Statistical analysis of microarray data of
two patient cells.
Additional file 6: Table S5. Ratios of various housekeeping genes
observed in microarray analysis.
Additional file 7: Table S6. Differentially expressed genes in TGCV
patient cells.
Additional file 8: Figure S2. Quantitative PCR confirms differential
expression of genes between TGCV patient cells and control cells.
Additional file 9: Table S7. Networks of differentially expressed genes
in TGCV cells.Abbreviations
PBS: Phosphate-buffered saline; DTT: Dithiothreitol; LC-MS/MS: Liquid
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